Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04976634
Title Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

biliary tract cancer

intrahepatic cholangiocarcinoma

gallbladder cancer

colorectal cancer

hepatocellular carcinoma

pancreatic ductal adenocarcinoma

Therapies

Belzutifan + Lenvatinib + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | FRA | ESP

Additional content available in CKB BOOST